Literature DB >> 12135389

Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP.

Daisuke Okada1, Shigeki Asakawa.   

Abstract

The effects of cGMP binding on the catalytic activity of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) are unclear because cGMP interacts with both allosteric and catalytic sites specifically. We studied the effects of cGMP on the hydrolysis of a fluorescent substrate analogue, 2'-O-anthraniloyl cGMP, by PDE5 partially purified from rat cerebella. The preparation contained PDE5 as the major cGMP-PDE activity and was not contaminated with cAMP- or cGMP-dependent protein kinases. The Hill coefficients for hydrolysis of the analogue substrate were around 1.0 in the presence of cGMP at concentrations <0.3 microM, while they increased to 1.5 at cGMP concentrations >1 microM, suggesting allosteric activation by cGMP at concentrations close to the bulk binding constant of the enzyme. Consistent with an allosteric activation, increasing concentrations of cGMP enhanced the hydrolysis rate of fixed concentrations of 2'-O-anthraniloyl cGMP, which overcame competition between the two substrates. Such activation was not observed with cAMP, cyclic inosine 3',5'-monophosphate, or 2'-O-monobutyl cGMP, indicating specificity of cGMP. These results demonstrate that cGMP is a specific and allosteric activator of PDE5, and suggest that in cells containing PDE5, such as cerebellar Purkinje cells, intracellular cGMP concentrations may be regulated autonomously through effects of cGMP on PDE5.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135389     DOI: 10.1021/bi025727+

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  PDE5 is converted to an activated state upon cGMP binding to the GAF A domain.

Authors:  Sergei D Rybalkin; Irina G Rybalkina; Masami Shimizu-Albergine; Xiao-Bo Tang; Joseph A Beavo
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

2.  In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation.

Authors:  Florian Mullershausen; Michael Russwurm; Doris Koesling; Andreas Friebe
Journal:  Mol Biol Cell       Date:  2004-07-07       Impact factor: 4.138

Review 3.  New insight into the functioning of nitric oxide-receptive guanylyl cyclase: physiological and pharmacological implications.

Authors:  John Garthwaite
Journal:  Mol Cell Biochem       Date:  2009-12-11       Impact factor: 3.396

4.  Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.

Authors:  Jackie D Corbin; Roya Zoraghi; Sharron H Francis
Journal:  Cell Signal       Date:  2009-08-06       Impact factor: 4.315

Review 5.  HBOC vasoactivity: interplay between nitric oxide scavenging and capacity to generate bioactive nitric oxide species.

Authors:  Pedro Cabrales; Joel M Friedman
Journal:  Antioxid Redox Signal       Date:  2013-02-12       Impact factor: 8.401

6.  Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.

Authors:  Kabir H Biswas; Sandhya S Visweswariah
Journal:  J Biol Chem       Date:  2010-12-29       Impact factor: 5.157

7.  A synthetic mimic of phosphodiesterase type 5 based on corona phase molecular recognition of single-walled carbon nanotubes.

Authors:  Juyao Dong; Michael A Lee; Ananth Govind Rajan; Imon Rahaman; Jessica H Sun; Minkyung Park; Daniel P Salem; Michael S Strano
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-14       Impact factor: 11.205

Review 8.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

9.  Mechanisms of activity-dependent plasticity in cellular nitric oxide-cGMP signaling.

Authors:  Edward J Halvey; Jeffrey Vernon; Brijesh Roy; John Garthwaite
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.